Evoke Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 153.6%.

Top 21 shareholders own 57.74% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10.1%	Laurence Lytton	859,322	US$417.2k	0%	no data
9.73%	Aigh Capital Management, LLC	825,000	US$400.5k	0%	0.15%
9.73%	Altium Capital Management LP	825,000	US$400.5k	0%	0.22%
9.73%	Bleichroeder LP	825,000	US$400.5k	0%	0.09%
8.67%	Lytton-Kambara Foundation, Endowment Arm	735,294	US$357.0k	0%	21.78%
7.96%	Nantahala Capital Management, LLC	675,000	US$327.7k	0%	0.03%
0.35%	The Vanguard Group, Inc.	29,851	US$14.5k	0%	no data
0.33%	David Gonyer	28,314	US$13.7k	0%	no data
0.33%	Cam Garner	27,966	US$13.6k	0%	no data
0.32%	Geode Capital Management, LLC	27,065	US$13.1k	0%	no data
0.23%	Matthew D'Onofrio	19,833	US$9.6k	0%	no data
0.076%	Tower Research Capital LLC	6,446	US$3.1k	11.3%	no data
0.051%	Marilyn Carlson	4,323	US$2.1k	0%	no data
0.034%	UBS Asset Management AG	2,914	US$1.4k	7.65%	no data
0.019%	Malcolm Hill	1,604	US$778.7	0%	no data
0.017%	BlackRock, Inc.	1,473	US$714.9	0%	no data
0.0044%	Morgan Stanley, Investment Banking and Brokerage Investments	375	US$181.9	0%	no data
0.0039%	Todd Brady	333	US$161.8	0%	no data
0.0024%	NewEdge Advisors, LLC	208	US$100.8	0%	no data
0.00033%	Royal Bank of Canada, Banking & Securities Investments	28	US$13.6	0%	no data
0.00031%	Wells Fargo & Company, Private Banking and Investment Banking Arm	26	US$12.8	8.33%	no data